Kidney Cancer Drugs Market Trends, Size, Growth, Demand Revenue and Future Outlook

Kidney Cancer Drugs Market Growth, Size, Trends Analysis - By Cancer Type, By Therapy, By Drug Class, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Q: How can I get a sample report on the Kidney Cancer Drugs Market?

You can get the sample pages by clicking the link - Click Here

Published: Mar-2025	Report ID: PHAR2504	Pages: 1 - 261	Formats^*:
Category : Pharmaceutical

Kidney Cancer Drugs Market Introduction and Overview

According to SPER Market Research, the Global Kidney Cancer Drugs Market is estimated to reach USD 11.56 billion by 2034 with a CAGR of 5.83%.

The report includes an in-depth analysis of the Global Kidney Cancer Drugs Market, including market size and trends, product mix, Applications, and supplier analysis.

The Kidney Cancer Drugs market was valued at USD 6.56 billion in 2024 and is expected to grow at a rate of 5.83% from 2025 to 2034. This growth is due to improvements in treatments, rising kidney cancer cases, higher healthcare spending, and new drug developments. The increase in kidney cancer is linked to aging populations, lifestyle changes like smoking and obesity, and environmental factors, leading to a need for better treatment options.

By Cancer Type Insights: Based on cancer type, the market is divided into renal cell carcinoma (RCC), transitional cell cancer, Wilms tumor, and renal sarcoma. In 2024, RCC generated the highest revenue. The incidence of RCC is increasing globally due to aging populations, lifestyle changes, and environmental factors. RCC is the most common kidney cancer, accounting for over 90% of adult kidney malignancies, which boosts market growth. Furthermore, the use of kidney cancer drugs, especially targeted therapies and immunotherapies, is expanding. Clinical trials are testing these drugs in earlier RCC stages and alongside other treatments, providing more options for patients and supporting market growth.

By Therapy Insights: Based on therapy, the kidney cancer drugs market is divided into targeted therapy, immunotherapy, chemotherapy, and other therapies. The targeted therapy segment led the market in 2024 with the largest share. A better understanding of the molecular biology and signaling pathways in kidney cancer has helped identify specific molecular targets for treatment. Targeted therapies focus on blocking these faulty signaling pathways to stop tumor growth. Additionally, targeted therapies allow for a more personalized treatment approach. Biomarker-driven therapy, guided by genomic profiling and molecular diagnostics, helps doctors customize treatment plans based on individual patient traits and genetic information, improving effectiveness and reducing side effects for better patient outcomes.

By Drug Class Insights: The kidney cancer drugs market is divided into different drug classes: angiogenesis inhibitors, monoclonal antibodies, mTOR inhibitors, cytokine immunotherapy (IL-2), and others. Angiogenesis inhibitors are expected to hold the largest market share in 2024 due to their proven benefits in treating kidney cancer. Clinical trials indicate these drugs improve survival rates for patients with advanced kidney cancer. They are often used alongside other treatments, such as immune checkpoint inhibitors or chemotherapy, to enhance effectiveness, which is likely to drive market growth.

By Route of Administration Insights: Based on route of administration, the kidney cancer drugs market is divided into oral, intravenous, and subcutaneous methods. The oral segment is the largest and is expected to grow the fastest from 2025 to 2034. Oral medications are more convenient than traditional intravenous or intramuscular injections. The use of these drugs at home reduces the need for frequent visits to hospitals and allows patients to focus on their daily lives while battling cancer. Additionally, oral medications increase treatment options for kidney cancer patients. Some may prefer oral drugs for personal or medical reasons, enabling healthcare providers to customize treatment plans and improve patient satisfaction and involvement in their care.

By Distribution Channel Insights: The kidney cancer drugs market is divided into hospital pharmacy, brick and mortar, and e-commerce. In 2024, the hospital pharmacy segment led the market. Hospital pharmacies manage and dispense kidney cancer medications. Pharmacists verify prescriptions, ensure proper dosing, and advise patients on medication use, side effects, and adherence. Their expertise helps improve medication plans, reduce errors, and enhance patient safety in kidney cancer treatment. Additionally, these pharmacies offer compounding services to create customized medications for patients needing specific dosages or formulations not available commercially. Pharmacists collaborate with healthcare providers to ensure effective treatment and patient satisfaction.

Regional Insights: North America's kidney cancer drugs market was expected to be the largest in 2024 due to its strong healthcare infrastructure, advanced medical facilities, and access to innovative treatments. The presence of top pharmaceutical companies and research institutions has also encouraged development in kidney cancer therapy. The Asia Pacific kidney cancer drugs market is projected to grow the fastest, driven by its large population and rising life expectancy, which have increased kidney cancer cases. Greater awareness and better healthcare access have boosted the demand for effective treatments.

Get more information on this report: Download Free Sample PDF

Market Competitive Landscape

The kidney cancer drugs industry is dominated by major pharmaceutical companies like Pfizer Inc., Novartis AG, and Bayer AG, which provide innovative treatments such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. These companies focus on research and development to meet medical needs and offer more treatment options. Emerging biotech firms are also developing promising drugs. As kidney cancer cases rise globally, the demand for effective treatments grows, leading to increased competition and better patient outcomes.

Recent Developments:

Merck declared in September 2023 that the FDA had given its supplemental new drug application (sNDA) for WELIREG, an oral inhibitor of hypoxia-inducible factor-2 alpha (HIF-2Î±), priority review. The oral inhibitor is intended to treat adult patients with advanced renal cell carcinoma (RCC) following immune checkpoint and anti-angiogenic therapies.

Belzutifan was created by a UTSW spinoff at UT Southwestern Medical Centre and authorised by the FDA in December 2023 for the treatment of metastatic kidney cancer.

Scope of the Report:

Report Metric	Details
Market size available for years	2021-2034
Base year considered	2024
Forecast period	2025-2034
Segments covered	By Cancer Type, By Therapy, By Drug Class, By Route of Administration, By Distribution Channel.
Regions covered	North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.
Companies Covered	Active Biotech AB, Amgen, Inc, Astellas Pharma Inc, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd, Exelixis, Inc, F. Hoffmann-La Roche Ltd, Genentech, Inc, GSK plc, Helsinn Healthcare SA, Johnson & Johnson Services, Inc, Merck & Co., Inc.

Key Topics Covered in the Report

Global Kidney Cancer Drugs Market Size (FYâ€™2021-FYâ€™2034)
Overview of Global Kidney Cancer Drugs Market
Segmentation of Global Kidney Cancer Drugs Market By Cancer Type (Renal cell carcinoma, Transitional cell cancer, Wilms tumor, Renal sarcoma)
Segmentation of Global Kidney Cancer Drugs Market By Therapy (Targeted therapy, Immunotherapy, Chemotherapy, Other therapies)
Segmentation of Global Kidney Cancer Drugs Market By Drug Class (Angiogenesis inhibitors, Monoclonal antibodies, mTOR inhibitors, Cytokine immunotherapy, Other drug classes)
Segmentation of Global Kidney Cancer Drugs Market By Route of Administration (Oral, Intravenous, Subcutaneous)
Segmentation of Global Kidney Cancer Drugs Market By Distribution Channel (Hospital pharmacy, Brick and mortar, E-commerce)
Statistical Snap of Global Kidney Cancer Drugs Market
Expansion Analysis of Global Kidney Cancer Drugs Market
Problems and Obstacles in Global Kidney Cancer Drugs Market
Competitive Landscape in the Global Kidney Cancer Drugs Market
Details on Current Investment in Global Kidney Cancer Drugs Market
Competitive Analysis of Global Kidney Cancer Drugs Market
Prominent Players in the Global Kidney Cancer Drugs Market
SWOT Analysis of Global Kidney Cancer Drugs Market
Global Kidney Cancer Drugs Market Future Outlook and Projections (FYâ€™2025-FYâ€™2034)
Recommendations from Analyst

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source

2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs

2.2. Market size estimation

2.2.1. Top-down and Bottom-up approach

2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis

4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis

5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats

5.2. PESTEL Analysis

5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape

5.3. PORTERs Five Forces

5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry

5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Kidney Cancer Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Kidney Cancer Drugs Market

7. Global Kidney Cancer Drugs Market, By Cancer Type (USD Million) 2021-2034

7.1. Renal cell carcinoma (RCC)
7.2. Transitional cell cancer
7.3. Wilms tumor
7.4. Renal sarcoma

8. Global Kidney Cancer Drugs Market, By Therapy (USD Million) 2021-2034

8.1. Targeted therapy
8.2. Immunotherapy
8.3. Chemotherapy
8.4. Other therapies

9. Global Kidney Cancer Drugs Market, By Drug Class (USD Million) 2021-2034

9.1. Angiogenesis inhibitors
9.2. Monoclonal antibodies
9.3. mTOR inhibitors
9.4. Cytokine immunotherapy (IL-2)
9.5. Other drug classes

10. Global Kidney Cancer Drugs Market, By Route of Administration (USD Million) 2021-2034

10.1. Oral
10.2. Intravenous
10.3. Subcutaneous

11. Global Kidney Cancer Drugs Market, By Distribution Channel (USD Million) 2021-2034

11.1. Hospital pharmacy
11.2. Brick and mortar
11.3. E-commerce

12. Global Kidney Cancer Drugs Market, (USD Million) 2021-2034

12.1. Global Kidney Cancer Drugs Market Size and Market Share

13. Global Kidney Cancer Drugs Market, By Region, (USD Million) 2021-2034

13.1. Asia-Pacific

13.1.1. Australia
13.1.2. China
13.1.3. India
13.1.4. Japan
13.1.5. South Korea
13.1.6. Rest of Asia-Pacific

13.2. Europe

13.2.1. France
13.2.2. Germany
13.2.3. Italy
13.2.4. Spain
13.2.5. United Kingdom
13.2.6. Rest of Europe

13.3. Middle East and Africa

13.3.1. Kingdom of Saudi Arabia
13.3.2. United Arab Emirates
13.3.3. Qatar
13.3.4. South Africa
13.3.5. Egypt
13.3.6. Morocco
13.3.7. Nigeria
13.3.8. Rest of Middle-East and Africa

13.4. North America

13.4.1. Canada
13.4.2. Mexico
13.4.3. United States

13.5. Latin America

13.5.1. Argentina
13.5.2. Brazil
13.5.3. Rest of Latin America

14. Company Profile

14.1. Active Biotech AB

14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments

14.2. Amgen, Inc

14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments

14.3. Astellas Pharma Inc

14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments

14.4. AstraZeneca PLC

14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments

14.5. Bayer AG

14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4. Recent developments

14.6. Bristol-Myers Squibb Company

14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments

14.7. Eisai Co., Ltd

14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments

14.8. Exelixis, Inc

14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments

14.9. F. Hoffmann-La Roche Ltd

14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments

14.10. Genentech, Inc

14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary
14.10.4. Recent developments

14.11. GSK plc

14.11.1. Company details
14.11.2. Financial outlook
14.11.3. Product summary
14.11.4. Recent developments

14.12. Helsinn Healthcare SA

14.12.1. Company details
14.12.2. Financial outlook
14.12.3. Product summary
14.12.4. Recent developments

14.13. Johnson & Johnson Services, Inc

14.13.1. Company details
14.13.2. Financial outlook
14.13.3. Product summary
14.13.4. Recent developments

14.14. Merck & Co., Inc

14.14.1. Company details
14.14.2. Financial outlook
14.14.3. Product summary
14.14.4. Recent developments

14.15. Others

15. Conclusion

16. List of Abbreviations

17. Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3

Frequently Asked Questions About This Report

What is the anticipated CAGR of the Kidney Cancer Drugs Market?

Kidney Cancer Drugs Market CAGR of 5.83% during the forecast period.

How can I get a sample report on the Kidney Cancer Drugs Market?

You can get the sample pages by clicking the link - Click Here

What is the Market size of the Kidney Cancer Drugs Market?

Kidney Cancer Drugs Market size is USD 11.56 billion from 2025 to 2034.

Which segment is expected to Kidney Cancer Drugs Market?

Kidney Cancer Drugs Market is covered By Product, By Function, By Application, By End-User.

Which region is expected to have the highest Market share in the Kidney Cancer Drugs Market?

The North America is anticipated to have the highest Market share in the Kidney Cancer Drugs Market.

Who are the key players in Kidney Cancer Drugs Market?

The key players in the Market include Companies Covered Active Biotech AB, Amgen, Inc, Astellas Pharma Inc, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd, Exelixis, Inc, F. Hoffmann-La Roche Ltd, Genentech, Inc, GSK plc, Helsinn Healthcare SA, Johnson & Johnson Services, Inc, Merck & Co., Inc.

What is the conclusion of the Kidney Cancer Drugs Market?

How big is the Kidney Cancer Drugs Market?

Kidney Cancer Drugs Market is projected to reach USD 11.56 billion by 2034, growing at a CAGR of 5.83% during the forecast period.

What is the growth rate of the Kidney Cancer Drugs Market?

Kidney Cancer Drugs Market grew in Market size from 2025. The Market is expected to reach USD 11.56 billion by 2034, at a CAGR of 5.83% during the forecast period.